homefeedbacksupportlog on 6-Sep-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


Albert Deisseroth
Sidney Kimmel Cancer Center, United States of America

Faculty Member: Pharmacology & Drug Discovery > Cancer Therapeutics [ since 28 April 2006 ]
[ Evaluations ]
to email [Help]
Evaluations

Molecular definition of breast tumor heterogeneity.
Shipitsin M, Campbell LL, …, Gelman RS, Polyak K
Cancer Cell 2007 Mar 11(3):259-73 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Takashi Tsuruo / Matthew John Smalley / Albert Deisseroth
Evaluated 1 May 2007

The prognostic role of a gene signature from tumorigenic breast-cancer cells.
Liu R, Wang X, …, Shedden K, Clarke MF
N Engl J Med 2007 Jan 18 356(3):217-26 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Robert Copeland / Albert Deisseroth
Evaluated 1 May 2007


A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
O'Brien CA, Pollett A, Gallinger S, Dick JE
Nature 2007 Jan 4 445(7123):106-10 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Takashi Tsuruo / Matthew John Smalley / Silvana Curci / Thomas Ried / Ulf Pettersson / Albert Deisseroth
Evaluated 1 May 2007

Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
Jin L, Hope KJ, …, Smadja-Joffe F, Dick JE
Nat Med 2006 Oct 12(10):1167-74 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Matthew John Smalley / Albert Deisseroth
Evaluated 1 May 2007

^Top  Back to Faculty Members



© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info